SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
Dated
February 28, 2005
IMI International Medical Innovations
Inc.
Commission
File Number 1-31360
615-4211
Yonge Street
Toronto,
Ontario M2P 2A9
CANADA
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
"Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ________
IMI International Medical Innovations
Inc.
Form
6-K
On
February 28, 2005, the
Corporation issued a press release announcing that amendments approved last week
by the U.S. Food and Drug Administration (FDA) to accelerate AtheroGenics,
Inc.’s ARISE clinical trial and increase patient enrollment will provide IMI
International Medical Innovations Inc. (TSX:IMI; Amex: IME) with valuable new
data on skin sterol and its relationship to primary events such as heart attacks
and stroke sooner than expected. The information contained in the press release
is incorporated herein by reference and filed as Exhibit 99.1.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
|
|
| |
IMI International
Medical Innovations Inc. |
|
|
|
| |
By: |
/s/ Ronald G.
Hosking |
| |
|
| |
Ronald G. Hosking |
| |
Vice President and Chief Financial
Officer |
Date:
February 28, 2005
EXHIBIT
INDEX
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
| 99.1 |
|
The Registrant’s Press Release |
| |
|
Dated
February 28, 2005 |